There are 2137 resources available
942P - Genomic characterization reveals potential therapeutic targets in nasopharyngeal carcinoma with relapse
Presenter: William Cho
Session: E-Poster Display
Resources:
Abstract
943P - The most optimal induction chemotherapy regimen for loco-regionally advanced nasopharyngeal carcinoma: A network meta-analysis
Presenter: Sik Kwan Chan
Session: E-Poster Display
Resources:
Abstract
944P - The prognostic role of COP-NLR score (combination of platelet count and neutrophil to lymphocyte ratio) in locally advanced nasopharyngeal cancer patients
Presenter: Agus Achmad
Session: E-Poster Display
Resources:
Abstract
945P - Association of Epstein-Barr virus infection with peripheral immune parameters and clinical outcome in advanced nasopharyngeal carcinomas
Presenter: Dan Tao
Session: E-Poster Display
Resources:
Abstract
946P - Germinal immunogenetics and response to nivolumab in recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC) patients (pts): TopNIVO ancillary study
Presenter: Esma Saada
Session: E-Poster Display
Resources:
Abstract
947P - Association between genetic variants and cisplatin nephrotoxicity: A genome-wide approach
Presenter: Zulfan Zazuli
Session: E-Poster Display
Resources:
Abstract
948P - Pre-treatment characteristics and long-term outcomes of recurrent-metastatic head and neck cancer patients treated with immune checkpoint inhibitors
Presenter: Majd Issa
Session: E-Poster Display
Resources:
Abstract
949P - Impact of antibiotic use and derived neutrophil to lymphocyte ratio (dNLR) in patients with recurrent/metastatic head and neck squamous cell cancer (R/M HNSCC) treated with immunotherapy
Presenter: Maria Plana
Session: E-Poster Display
Resources:
Abstract
950P - Prognostic and predictive value of skeletal muscle mass (SMM) in squamous cell carcinoma of the head and neck (SCCHN) in patients treated with immune checkpoint inhibitors (ICI)
Presenter: Lorena Arribas
Session: E-Poster Display
Resources:
Abstract
951P - The relationship between overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) in immune checkpoint inhibitor clinical trials of head and neck squamous cell carcinoma (HNSCC): A systematic review and meta-analysis
Presenter: Xiaowei Wang
Session: E-Poster Display
Resources:
Abstract